Open angle glaucoma and related optic neuropathies are a leading cause of irreversible blindness worldwide and are characterized by progressive loss of retinal ganglion cells, atrophy of the optic nerve and severe visual field deficits. The major risk factor for open angle glaucoma is increased intraocular pressure (IOP) resulting from an imbalance between aqueous humor production and outflow. As such, the standard clinical therapy is to reduce IOP through a combination of topical drug administration and surgery. The major clinical challenge is that due to the largely asymptomatic (i.e. non-painful) nature of the disease and the need to maintain a lifelong daily treatment regimen, patient compliance is extremely poor, often leading to the development of sight threatening complications, even in patients diagnosed early. In this talk we will present our progress towards the development of an alternative therapeutic approach using gene therapy to permanently lower IOP in open angle glaucoma following a single therapeutic intervention.
- Clinical eye care
- Medical Students
- Community Physicians
Participants who engage in this educational intervention will be able to:
- Articulate the need for novel, long-acting therapeutics for open angle glaucoma.
- Evaluate the potential of gene therapy to permanently lower intra-ocular pressure following a single vector dose.
- Relate to the need for rigorous pre-clinical testing in multiple animal models, especially for the treatment of complex disease.
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
Daniel M. Lipinski, MD
Ophthalmology and Visual Sciences, Research
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals.
The Medical College of Wisconsin, Inc. is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 150930. This program has been approved for up to 1.00 contact hours of continuing education (which includes 1.00 hours of pharmacology). Nurse Practitioners should claim only those hours actually spent participating in the CME activity.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.